Literature DB >> 20345981

A role for human endogenous retrovirus-K (HML-2) in rheumatoid arthritis: investigating mechanisms of pathogenesis.

G Freimanis1, P Hooley, H Davari Ejtehadi, H A Ali, A Veitch, P B Rylance, A Alawi, J Axford, A Nevill, P G Murray, P N Nelson.   

Abstract

Human endogenous retroviruses (HERVs) are remnants of ancient retroviral infections within the human genome. These molecular fossils draw parallels with present-day exogenous retroviruses and have been linked previously with immunopathology within rheumatoid arthritis (RA). Mechanisms of pathogenesis for HERV-K in RA such as molecular mimicry were investigated. To clarify a role for HERVs in RA, potential autoantigens implicated in autoimmunity were scanned for sequence identity with retroviral epitopes. Short retroviral peptides modelling shared epitopes were synthesized, to survey anti-serum of RA patients and disease controls. A novel real-time polymerase chain reaction (PCR) assay was also developed to quantify accurately levels of HERV-K (HML-2) gag expression, relative to normalized housekeeping gene expression. Both serological and molecular assays showed significant increases in HERV-K (HML-2) gag activity in RA patients, compared to disease controls. The real-time PCR assay identified significant up-regulation in HERV-K mRNA levels in RA patients compared to inflammatory and healthy controls. Exogenous viral protein expression and proinflammatory cytokines were also shown to exert modulatory effects over HERV-K (HML-2) transcription. From our data, it can be concluded that RA patients exhibited significantly elevated levels of HERV-K (HML-2) gag activity compared to controls. Additional factors influencing HERV activity within the synovium were also identified. The significant variation in RA patients, both serologically and transcriptionally, may be an indication that RA is an umbrella term for a number of separate disease entities, of which particular HERV polymorphisms may play a role in development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345981      PMCID: PMC2883104          DOI: 10.1111/j.1365-2249.2010.04110.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Initial sequencing and analysis of the human genome.

Authors:  E S Lander; L M Linton; B Birren; C Nusbaum; M C Zody; J Baldwin; K Devon; K Dewar; M Doyle; W FitzHugh; R Funke; D Gage; K Harris; A Heaford; J Howland; L Kann; J Lehoczky; R LeVine; P McEwan; K McKernan; J Meldrim; J P Mesirov; C Miranda; W Morris; J Naylor; C Raymond; M Rosetti; R Santos; A Sheridan; C Sougnez; Y Stange-Thomann; N Stojanovic; A Subramanian; D Wyman; J Rogers; J Sulston; R Ainscough; S Beck; D Bentley; J Burton; C Clee; N Carter; A Coulson; R Deadman; P Deloukas; A Dunham; I Dunham; R Durbin; L French; D Grafham; S Gregory; T Hubbard; S Humphray; A Hunt; M Jones; C Lloyd; A McMurray; L Matthews; S Mercer; S Milne; J C Mullikin; A Mungall; R Plumb; M Ross; R Shownkeen; S Sims; R H Waterston; R K Wilson; L W Hillier; J D McPherson; M A Marra; E R Mardis; L A Fulton; A T Chinwalla; K H Pepin; W R Gish; S L Chissoe; M C Wendl; K D Delehaunty; T L Miner; A Delehaunty; J B Kramer; L L Cook; R S Fulton; D L Johnson; P J Minx; S W Clifton; T Hawkins; E Branscomb; P Predki; P Richardson; S Wenning; T Slezak; N Doggett; J F Cheng; A Olsen; S Lucas; C Elkin; E Uberbacher; M Frazier; R A Gibbs; D M Muzny; S E Scherer; J B Bouck; E J Sodergren; K C Worley; C M Rives; J H Gorrell; M L Metzker; S L Naylor; R S Kucherlapati; D L Nelson; G M Weinstock; Y Sakaki; A Fujiyama; M Hattori; T Yada; A Toyoda; T Itoh; C Kawagoe; H Watanabe; Y Totoki; T Taylor; J Weissenbach; R Heilig; W Saurin; F Artiguenave; P Brottier; T Bruls; E Pelletier; C Robert; P Wincker; D R Smith; L Doucette-Stamm; M Rubenfield; K Weinstock; H M Lee; J Dubois; A Rosenthal; M Platzer; G Nyakatura; S Taudien; A Rump; H Yang; J Yu; J Wang; G Huang; J Gu; L Hood; L Rowen; A Madan; S Qin; R W Davis; N A Federspiel; A P Abola; M J Proctor; R M Myers; J Schmutz; M Dickson; J Grimwood; D R Cox; M V Olson; R Kaul; C Raymond; N Shimizu; K Kawasaki; S Minoshima; G A Evans; M Athanasiou; R Schultz; B A Roe; F Chen; H Pan; J Ramser; H Lehrach; R Reinhardt; W R McCombie; M de la Bastide; N Dedhia; H Blöcker; K Hornischer; G Nordsiek; R Agarwala; L Aravind; J A Bailey; A Bateman; S Batzoglou; E Birney; P Bork; D G Brown; C B Burge; L Cerutti; H C Chen; D Church; M Clamp; R R Copley; T Doerks; S R Eddy; E E Eichler; T S Furey; J Galagan; J G Gilbert; C Harmon; Y Hayashizaki; D Haussler; H Hermjakob; K Hokamp; W Jang; L S Johnson; T A Jones; S Kasif; A Kaspryzk; S Kennedy; W J Kent; P Kitts; E V Koonin; I Korf; D Kulp; D Lancet; T M Lowe; A McLysaght; T Mikkelsen; J V Moran; N Mulder; V J Pollara; C P Ponting; G Schuler; J Schultz; G Slater; A F Smit; E Stupka; J Szustakowki; D Thierry-Mieg; J Thierry-Mieg; L Wagner; J Wallis; R Wheeler; A Williams; Y I Wolf; K H Wolfe; S P Yang; R F Yeh; F Collins; M S Guyer; J Peterson; A Felsenfeld; K A Wetterstrand; A Patrinos; M J Morgan; P de Jong; J J Catanese; K Osoegawa; H Shizuya; S Choi; Y J Chen; J Szustakowki
Journal:  Nature       Date:  2001-02-15       Impact factor: 49.962

2.  A neural-network based method for prediction of gamma-turns in proteins from multiple sequence alignment.

Authors:  Harpreet Kaur; G P S Raghava
Journal:  Protein Sci       Date:  2003-05       Impact factor: 6.725

3.  Effective method for synthetic peptide immobilization that increases the sensitivity and specificity of ELISA procedures.

Authors:  V S Ivanov; Z K Suvorova; L D Tchikin; A T Kozhich; V T Ivanov
Journal:  J Immunol Methods       Date:  1992-08-30       Impact factor: 2.303

4.  Molecular investigations implicate human endogenous retroviruses as mediators of anti-retroviral antibodies in autoimmune rheumatic disease.

Authors:  P N Nelson; A M Lever; S Smith; R Pitman; P Murray; S A Perera; O M Westwood; F C Hay; H D Ejtehadi; J C Booth
Journal:  Immunol Invest       Date:  1999-07       Impact factor: 3.657

Review 5.  Epstein-Barr virus etiology in rheumatoid synovitis.

Authors:  Shigemasa Sawada; Masami Takei
Journal:  Autoimmun Rev       Date:  2005-02       Impact factor: 9.754

Review 6.  Rheumatoid arthritis.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Immunol Rev       Date:  2005-04       Impact factor: 12.988

7.  Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen.

Authors:  N Sutkowski; B Conrad; D A Thorley-Lawson; B T Huber
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

Review 8.  The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases.

Authors:  John G Routsias; Athanasios G Tzioufas; Haralampos M Moutsopoulos
Journal:  Clin Chim Acta       Date:  2004-02       Impact factor: 3.786

Review 9.  Demystified. Human endogenous retroviruses.

Authors:  P N Nelson; P R Carnegie; J Martin; H Davari Ejtehadi; P Hooley; D Roden; S Rowland-Jones; P Warren; J Astley; P G Murray
Journal:  Mol Pathol       Date:  2003-02

Review 10.  Malignancy in autoimmune diseases.

Authors:  L J Kinlen
Journal:  J Autoimmun       Date:  1992-04       Impact factor: 7.094

View more
  39 in total

1.  Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1.

Authors:  Marta J Gonzalez-Hernandez; Michael D Swanson; Rafael Contreras-Galindo; Sarah Cookinham; Steven R King; Richard J Noel; Mark H Kaplan; David M Markovitz
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Divergent and dynamic activity of endogenous retroviruses in burn patients and their inflammatory potential.

Authors:  Kang-Hoon Lee; HyungChul Rah; Tajia Green; Young-Kwan Lee; Debora Lim; Jean Nemzek; Wendy Wahl; David Greenhalgh; Kiho Cho
Journal:  Exp Mol Pathol       Date:  2014-02-06       Impact factor: 3.362

3.  Prediction of Human Immunodeficiency Virus Type 1 Subtype-Specific Off-Target Effects Arising from CRISPR-Cas9 Gene Editing Therapy.

Authors:  Robert W Link; Michael R Nonnemacher; Brian Wigdahl; Will Dampier
Journal:  CRISPR J       Date:  2018-08

4.  Retroviral sero-reactivity in LGL leukaemia patients and family members.

Authors:  Susan B Nyland; David J Feith; Mary Poss; Thomas L Olson; Daniel J Krissinger; Bernard J Poiesz; Francis W Ruscetti; Thomas P Loughran
Journal:  Br J Haematol       Date:  2019-10-14       Impact factor: 6.998

Review 5.  Endogenous retrovirus-K and nervous system diseases.

Authors:  Mamneet Manghera; Jennifer Ferguson; Renée Douville
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

6.  Identification of a HERV-K env surface peptide highly recognized in Rheumatoid Arthritis (RA) patients: a cross-sectional case-control study.

Authors:  G Mameli; G L Erre; E Caggiu; S Mura; D Cossu; M Bo; M L Cadoni; A Piras; N Mundula; E Colombo; G Buscetta; G Passiu; L A Sechi
Journal:  Clin Exp Immunol       Date:  2017-05-09       Impact factor: 4.330

7.  Upregulation of Human Endogenous Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Toshie Saito; Kazuya Miyagawa; Shih-Yu Chen; Rasa Tamosiuniene; Lingli Wang; Orr Sharpe; Erik Samayoa; Daisuke Harada; Jan-Renier A J Moonen; Aiqin Cao; Pin-I Chen; Jan K Hennigs; Mingxia Gu; Caiyun G Li; Ryan D Leib; Dan Li; Christopher M Adams; Patricia A Del Rosario; Matthew Bill; Francois Haddad; Jose G Montoya; William H Robinson; Wendy J Fantl; Garry P Nolan; Roham T Zamanian; Mark R Nicolls; Charles Y Chiu; Maria E Ariza; Marlene Rabinovitch
Journal:  Circulation       Date:  2017-09-21       Impact factor: 29.690

8.  Regulation of the human endogenous retrovirus K (HML-2) transcriptome by the HIV-1 Tat protein.

Authors:  Marta J Gonzalez-Hernandez; James D Cavalcoli; Maureen A Sartor; Rafael Contreras-Galindo; Fan Meng; Manhong Dai; Derek Dube; Anjan K Saha; Scott D Gitlin; Gilbert S Omenn; Mark H Kaplan; David M Markovitz
Journal:  J Virol       Date:  2014-05-28       Impact factor: 5.103

9.  NF-κB and IRF1 Induce Endogenous Retrovirus K Expression via Interferon-Stimulated Response Elements in Its 5' Long Terminal Repeat.

Authors:  Mamneet Manghera; Jennifer Ferguson-Parry; Rongtuan Lin; Renée N Douville
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

10.  Autoantibodies Against Unmodified and Citrullinated Human Endogenous Retrovirus K Envelope Protein in Patients With Rheumatoid Arthritis.

Authors:  Xiaoxing Wang; Amanda Hefton; Kathryn Ni; Kennedy C Ukadike; Michael A Bowen; Mary Eckert; Anne Stevens; Christian Lood; Tomas Mustelin
Journal:  J Rheumatol       Date:  2021-08-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.